Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today is pleased to announce that its pioneering CAR-T ...

The future of medicine with CRISPR and CAR-T therapy, exploring ethical, societal, and accessibility challenges in healthcare ...

For years The Cult's iconic guitarist Billy Duffy enjoyed life touring the planet but he's told us how his prostate cancer ...

The addition of itacitinib to standard graft-versus-host-disease prophylaxis may reduce severe toxicities following ...

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the ...

Blood cancer patients in Christchurch and Auckland will soon have a chance to join an expanded clinical trial using their own ...

Dr Annalisa Morgan previews discussions on disease-modifying therapies, emerging treatments such as CAR T-cell therapy, and ...

The Malaghan Institute is one step closer to its goal of making CAR T-cell therapy a standard of care in New Zealand as its phase 2 clinical trial opens its doors in Christchurch and Auckland City ...

A patient has achieved over 18 years of remission from neuroblastoma, a type of nerve cell cancer, following treatment with ...

Clinical outcomes from a prospective study of comprehensive genomic testing in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). This is an ASCO Meeting Abstract from the ...

Few advancements in contemporary medicine have sparked as much enthusiasm and potential as CAR T-cell therapy.

In the wake of novel bispecific and chimeric antigen receptor T-cell therapies for various cancers, geography still plays a big role in patients' abilities to receive such treatments.